ReviewEuropean journal of clinical pharmacology2026
Zanubrutinib in B-cell lymphomas: from clinical pharmacology to therapeutic application.
Review in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeWhile zanubrutinib, a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, is known for its improved target selectivity, a systematic integration of its clinical pharmacology with efficacy and safety across diverse B-cell lymphomas - particularly highlighting its distinct pharmacokinetic and pharmacodynamic profile relative to other BTK inhibitors - is lacking. This review comprehensively summarizes zanubrutinib’s pharmacological characteristics, clinical trial and real-world outcomes, and adverse event management strategies, aiming to provide a clinically actionable resource for optimized and individualized therapy.
methodsWe conducted a structured literature search in PubMed, Embase, Cochrane Library, and Web of Science using keywords including “zanubrutinib,” “BGB-3111,” “BTK inhibitor,” and “B-cell lymphoma.” Relevant publications were critically reviewed to synthesize evidence on zanubrutinib’s pharmacokinetics, pharmacodynamics, clinical efficacy across indications, and management of adverse events, with an emphasis on mechanistic insights and practical clinical guidance.
resultsZanubrutinib demonstrates a favorable efficacy and safety profile supported by its distinct pharmacological characteristics. Its favorable pharmacokinetics include high central nervous system penetration and well-characterized metabolic pathways. Clinically, it induces deep and durable responses across multiple B-cell malignancies, supported by sustained BTK occupancy and a superior free-drug trough concentration relative to its half-inhibitory concentration (IC50). The safety profile is characterized by lower incidences of certain off-target toxicities (e.g., atrial fibrillation) compared to ibrutinib, though infections, bleeding, and cytopenias require vigilant management. Analysis of resistance mechanisms underscores the central role of BTK mutations (e.g., C481S, L528W), informing future therapeutic sequencing.
conclusionThis review underscores the value of a pharmacology-guided approach to maximizing zanubrutinib’s benefits, encompassing rational dosing, proactive toxicity management, and strategic positioning within the BTK inhibitor landscape. Future directions should prioritize combinatorial strategies to overcome resistance and therapeutic drug monitoring for precision dosing.
Indexed as
Identifiers
41553498What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.